Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 65 to 80

mTOR medicines for healthier aging in older adults

Official title: Characterization of mTOR Inhibitor Pharmacokinetics and Pharmacodynamics in Older Adults .

Run by University of Texas Southwestern Medical Center · NCT06727305 · Data updated 2026-11-12

This trial will test two mTOR drugs, sirolimus and everolimus, in people 65 and older to measure drug levels and see if they improve biomarkers of aging.

More Aging trials

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages65 Years to 80 Years
SexAll
Enrollment60 (estimated)
SponsorUniversity of Texas Southwestern Medical Center
Academic / other
Locations1 site (Dallas, Texas)
StatusRecruiting
StartedMay 11, 2026
Main results expectedSeptember 1, 2027
Study endsNovember 13, 2027
Registry record updatedJune 25, 2026
Trial IDNCT06727305 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are community-dwelling adults aged 65 or older who can understand and follow procedures and do not have severe kidney or liver disease, uncontrolled hypertension, recent major cardiovascular or hemorrhagic/thrombotic events, dementia, dependence in basic ADLs, or medications that significantly interact with sirolimus/everolimus.

Probably not a fit

Patients with creatinine clearance <30 mL/min, chronic liver disease, uncontrolled systolic blood pressure >160 mm Hg, recent CNS hemorrhage or recent thrombotic events without anticoagulation, recent heart failure or myocardial infarction, dementia, dependence in Katz ADLs, or taking drugs that alter sirolimus levels are unlikely to be eligible and may not benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1/2 interventional trial will give older adults short courses of sirolimus or everolimus and collect serial blood samples to define pharmacokinetics and pharmacodynamics in this age group. Researchers will measure a senescence-associated secretory phenotype (SASP) index at baseline and 3 months to see whether those biomarkers shift with treatment. The study also collects exploratory laboratory measures (ESR, CRP, S6K activity, mitochondrial function, metabolomics) and functional tests (walking speed, chair stand, standing balance, grip strength). Results are intended to define safe dosing and biological signals to guide larger trials of mTOR inhibitors for aging-related outcomes.

Why it matters

Potential benefit: If successful, the trial could identify safe dosing and show whether mTOR inhibitors alter aging-related biomarkers, laying groundwork for larger studies aimed at slowing functional decline.

How similar studies have gone: Prior animal studies and small human trials have suggested mTOR inhibitors can modify aging pathways and improve immune or metabolic markers, but robust PK/PD and aging-biomarker data in older adults are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Community-dwelling adults
2. Patients should be 65 Years and older
3. Patients is able to understand and follow trial procedures

Exclusion Criteria:

1. Creatinine clearance \<30 mL/min;
2. History of chronic liver disease;
3. Uncontrolled Hypertension (i.e., systolic blood pressure \>160 mm Hg);
4. Hemorrhagic central nervous system (CNS) event within 1 year from screening visit;
5. Thrombotic event (DVT,PE) within 1 year from screening visit if not on anticoagulation;
6. Planned major surgical procedures;
7. Cardiovascular diseases ( i.e., admission for heart failure or myocardial infarction within 12 months);
8. Taking medication that increase or decrease sirolimus blood concentrations;
9. Other investigational therapy received within 1 month prior to screening visit;
10. History of dementia; 11 Dependence in any Katz Basic Activities of Daily Living.

Where it's running

  • UT Southwestern Medical Center
    Dallas, Texas, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.